Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
Aptose Biosciences (APTO) plans to release its financial results for Q2 2020 on August 4, 2020, after market close. The results will provide insights into the company's performance and development in oncology therapeutics. The upcoming conference call is scheduled for 5 PM EDT on the same day, allowing investors to discuss the results. Aptose focuses on personalized cancer therapies addressing unmet medical needs, with investigational products like CG-806 and APTO-253 in clinical trials targeting hematological malignancies.
- Scheduled financial results announcement for Q2 2020 may indicate ongoing business developments.
- Focus on personalized cancer therapies might attract investor interest.
- No current financial metrics available to assess performance.
- -
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market.
| 15%; min-width: | |
| 15%; width: | 85%; width: |
| Date: | Tuesday, August 4, 2020 |
| Time: | 5:00 PM EDT |
| Dial In - Toll-Free: | 1 844-882-7834 |
| Dial In - International: | 1 574-990-9707 |
| Passcode: | 8367033 |
| Webcast: | LINK |
| Replay available through August 11, 2020: | |
| Dial In - Toll-Free: | 1 855-859-2056 |
| Dial In - International: | 1 404-537-3406 |
| Replay Passcode: | 8367033 |
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at https://www.aptose.com/investors/news-events/ir-calendar. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended June 30, 2020 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
| 25%; width: | 75%; width: |
| Aptose Biosciences Inc. | LifeSci Advisors, LLC |
| Greg Chow | Dan Ferry, Managing Director |
| Executive Vice President, CFO | 617-535-7746 |
| 650-718-5028 | Daniel@LifeSciAdvisors.com |
| gchow@aptose.com | |
| SMP Communications | |
| Susan Pietropaolo | |
| 201-923-2049 | |
| susan@smpcommunications.com |
FAQ
When will Aptose Biosciences release its Q2 2020 financial results?
What time is the Aptose conference call for Q2 2020 results?
What is the focus of Aptose Biosciences?
What are the investigational products developed by Aptose?
Where can I find Aptose's financial statements?
